C4 Therapeutics, a preclinical biotech developing small molecule protein degraders for cancer, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
C4 has four preclinical programs for its small molecule protein degraders. The company expects to submit an IND for its lead candidate in the fourth quarter of 2020 and begin a first-in-human Phase 1/2 clinical trial in the first half of 2021.
The Watertown, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol CCCC. C4 Therapeutics filed confidentially on August 6, 2020. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
